Bristol-Myers Squibb S.A.

• Bristol-Myers Squibb Company, Plaintiff-Appellee, v. Rhone-Poulenc Rorer, Inc., Rhone-Poulenc Rorer, S.A., and Centre National de La Recherche Scientifique, Defendants-Appellants. Rhone-Poulenc Rorer, Inc. and Rhone-Poulenc Rorer, S.A., Plaintiffs/Counterclaim Defendants-Appellants, and Centre National de La Recherche Scientifique, Counterclaim Defendant-Appellant, v. Bristol-Myers Squibb Company, Defendant/Counterclaimant-Appellee., 326 F.3d 1226 (Fed. Cir. 2003)

... to review the '277 patent application, the same Examiner who had reviewed the '011 patent applicat...

• Federal Circuits

• The Campaign for Scandinavia House: The Nordic Center in America

Leif Höegh Foundation Skanska AB Stolt-Nielsen S.A. $250,000-$499,000 ABB LTD Bristol-Myers Squibb Company The Estate of Edith Coulter Lena and Gilbert Kaplan LEGO Company/ LEGO Systems, Inc. Nordic Investment Bank The Barbro Osher Pro Suecia Foundation Hilppa and Joe L. Roby Skandia Statoil Marketing & Trading (U.S). Teekay Foundation $100,000-$249,999 The Absolut Company Aker RGI Louise and Karl Andren Axel Johnson Inc. The Bonnier G roup The Curtis L. Carlson Family Foundation Danske Bank Dunard Fund USA Ambassador and Mrs. Edward E. Elson Ericsson Inc. FINNAIR Niels W. Johnsen Nokia Corporation Nordea Orkla ASA SAS, Scandinavian Airlines SEB Saimi and Thor Soderholm Sally and Christian Sonne Mr. and Mrs. Robert D. Stuart, Jr.

• Scandinavian Review
• Vol. 97 Nbr. 1, April 2010

• Brand Name, Generic Drug Makers Fight for Market

NEW YORK - The marketers of the world's second largest-selling drug dodged a major threat to their revenues two months ago by reaching a deal to keep a generic competitor at bay until at least 2011. Now, 10 lawsuits have been filed over the settlement Sanofi- Aventis SA and Bristol-Myers Squibb Co. reached with Apotex Inc., a generic manufacturer challenging blood thinner Plavix's patent. The suits, filed by businesses, unions and health plans, allege the deal violates antitrust laws by denying access to cheap, generic versions of Plavix.

• Charleston Gazette
• May 27, 2006

• Premerger notification waiting periods; early terminations,

...Inc. 20051351.......... XM Satellite Radio Holdings WCS Wireless, Inc..... WCS Wireless...Novartis AG........ Bristol Myers Squibb. Bristol Myers Squibb Company. Company. 20051374.....

• FR, September 08, 2005
• Notices
• Federal Trade Commission

• Generics to Rewrite Best-Selling Drug List

The 25 top-selling medicines last year targeted persistent illnesses such as high cholesterol, stomach ulcers and depression that drug makers can highlight to patients in television commercials and magazine ads. Cheaper competition may hurt some of these products this year. Pfizer Inc.'s cholesterol-cutting Lipitor was the best-selling treatment for the fifth year in a row, bringing in $12.2 billion in 2005, according to data compiled by Bloomberg. Plavix, the clot treatment sold by Sanofi-Aventis SA and Bristol-Myers Squibb Co., rose to No. 2 with $6.3 billion in sales. Advair, a GlaxoSmithKline PLC asthma drug, had sales of $5.5 billion, pushing it up a spot to third.

• The Record, Bergen County, NJ
• February 16, 2006

• States Reject Plan to Keep Generic Plavix Off Market

WASHINGTON U.S. states objected to a plan by Bristol-Myers Squibb Co. and Sanofi-Aventis SA to keep a generic copy of their top- selling blood-thinner Plavix off the market, reviving a dispute over the product's patent. An agreement to pay closely held Apotex Inc. not to sell a cheaper copy of the $4-a-day pill didn't comply with a 2003 agreement involving Bristol-Myers, attorneys general representing the 50 states said Friday. The states had sued Bristol-Myers on allegations it misused patents to thwart low-cost rivals.

• The Record, Bergen County, NJ
• July 31, 2006

• Effort to Block Generic Drug Draws Attention of the Ftc ; Documents From Bristol-Myers, Sanofi Sought

NEW YORK Bristol-Myers Squibb Co. and Sanofi-Aventis SA received demands from U.S. antitrust regulators for documents related to an unsuccessful bid last year to delay generic competition to the blood thinner Plavix. The U.S. Federal Trade Commission served the drug makers last month with formal requests for records connected with a settlement that the companies made with a Canadian company to stall sales of cheaper, copycat pills, Bristol-Myers and Sanofi said Tuesday in regulatory filings.

• The Record, Bergen County, NJ
• April 04, 2007

• Bristol-Myers, Sanofi-Aventis Try to Block Sale of Generic Plavix

Bristol-Myers Squibb Co. and Sanofi-Aventis SA said Monday they filed an injunction against Apotex Corp. to stop the Canadian drug maker from selling a less expensive, generic version of the blood thinner Plavix. They also said they have begun discounting Plavix to stem the loss of the drug's market share. A hearing on the motion is set for Friday in the U.S. District Court for the Southern District of New York, where the injunction was filed and a patent case on Plavix is pending.

• Evansville Courier & Press
• August 17, 2006

• Business Briefs

Injunction on generic drug filed NEW YORK - Bristol-Myers Squibb Co. and Sanofi-Aventis SA said Monday they filed an injunction against Apotex Corp. to stop the Canadian drug maker from selling a less expensive, generic version of the blood thinner Plavix. They also said they have begun discounting Plavix to stem the loss of the drug's market share.

• Press Telegram
• August 15, 2006

• Bristol, Sanofi Seek to Stop Sale of Generic Plavix

Bristol-Myers Squibb Co. and Sanofi-Aventis SA said Monday that they filed a request for an injunction against Apotex Corp. to stop the Canadian drug maker from selling a less expensive, generic version of the blood thinner Plavix. They also said they have begun discounting Plavix to stem the loss of the drug's market share. A hearing is set for Friday in the U.S. District Court for the Southern District of New York, where the motion for an injunction was filed and a patent case on Plavix is pending.

• The Record, Bergen County, NJ
• August 15, 2006